SCHEDULE: Biotech Fund Group Files Joint Ownership Statement

Several Biotechnology Value Funds and Mark N. Lampert have filed a joint statement detailing their beneficial ownership of Tyra Biosciences, Inc. common stock.

Summary

• This filing is a Joint Filing Agreement for a Schedule 13G concerning the common stock of Tyra Biosciences, Inc.
• It details the agreement among various Biotechnology Value Funds (BVF L.P., BVF II L.P., Trading Fund OS LP, Partners OS Ltd., Partners L.P./IL, BVF Inc./IL) and Mark N. Lampert to file a joint statement regarding their beneficial ownership.
• The filing specifies the date of the event requiring the Schedule 13G as September 14, 2026.
• As of September 21, 2026, the reporting persons collectively beneficially owned 6.1% of Tyra Biosciences, Inc. common stock, amounting to 4,215,886 shares.
• Individual holdings and shared voting/dispositive powers are detailed among the various entities and Mark N. Lampert.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily an administrative agreement for joint filing of beneficial ownership information, with no new financial or strategic information provided.

Positives

• The filing confirms a coordinated approach to beneficial ownership reporting among related entities, suggesting organized investment management.
• The aggregate ownership of 6.1% indicates a significant stake in Tyra Biosciences, Inc. by the Biotechnology Value Fund group.

Negatives

• The filing does not contain any new financial performance data, strategic updates, or operational information about Tyra Biosciences, Inc.
• It is purely an administrative filing related to ownership disclosure.

Risks

• The filing does not explicitly mention any risks related to Tyra Biosciences, Inc. or the reporting persons' holdings.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Tyra Biosciences, Inc.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and investment funds to report significant beneficial ownership stakes. This filing indicates that the Biotechnology Value Fund group maintains a notable position in Tyra Biosciences, Inc., a company operating within the biotechnology sector.

Stakeholder Impact

• Shareholders of Tyra Biosciences, Inc. are informed of the aggregate beneficial ownership held by the Biotechnology Value Fund group, which may influence market perception and trading activity.

Next Steps

• The reporting persons will continue to file amendments to Schedule 13G as required by SEC regulations.

Key Dates

Keywords

Tyra Biosciences, Schedule 13G, Beneficial Ownership, Biotechnology Value Fund, Mark N. Lampert, Joint Filing Agreement, Investment Management